The role of PI-3 kinase in cancer biology and approaches to the therapeutics of cancer
Many types of immune cellular stimulation or toxic insults activate the generalized systemic PI3K/AKT pathway and it regulates the basic cellular functions such as transcription, proliferation, growth and survival. The modified and disturbed activation of these pathway result in development of major disease such as cancer, diabetes mellitus and autoimmune disorders. Especially, PI3K/AKT mediated signal transduction molecules and effects on gene expression that contribute to tumorigenesis. Current evidence has suggested that the PI3K/AKT pathway is visible target for novel antitherapeutic drugs. Importantly, the main objectives of the signal transduction based research are to develop effective, low cost chemotherapeutic drugs that target very dangerous cancerous cells without affecting the normal cells. Small interfering RNA (siRNA) is one of the very effective therapeutic models in cancerous gene to inhibit or mimic the PI3K/AKT pathway for anticancer treatment. Many biological, active chemotherapeutic drugs have developed to inhibit the PI3K/AKT signaling pathways. This review will focus on the PI3K/AKT pathways, its alteration in cancer progression and different chemotherapeutic drugs have been used to inhibit the different types of cancer.